中国药房2016，Vol.27Issue(29)：4147-4149,3.DOI:10.6039/j.issn.1001-0408.2016.29.38
重组人表皮生长因子联合硫辛酸治疗糖尿病足的临床观察
Clinical Observation of Recombinant Human Epidermal Growth Factor Combined with Lipoic Acid in the Treatment of Diabetic Foot
张祥运 1丁晓斌 2林秀峰 1杨平 1林凯1
作者信息
- 1. 四川省医学科学院/四川省人民医院城东病区胃肠烧伤科，成都 610000
- 2. 西南医科大学附属医院整形烧伤科，四川泸州 646000
- 折叠
摘要
Abstract
OBJECTIVE:To investigate the clinical efficacy and safety of recombinant human epidermal growth factor(rhEGF) combined with lipoic acid in the treatment of diabetic foot. METHODS:A total of 68 patients with diabetic foot were randomly divid-ed into observation group and control group with 34 cases in each group. Both groups were given conventional therapy and Lipolic acid injection 0.6 ml added into Sodium chloride injection 250 ml. ivgtt(protecting form light),qd;observation group was additionally giv-en rhEGF for external use 1 ml and vaseline on the wounds,gauze dressing,qd. Treatment course of 2 groups lasted for 7 d. Clinical efficacy,ulcer area,the expression of Bcl-2 and Bax were compared between 2 groups as well as the occurrence of ADR. RESULTS:The total effective rate of observation group(94.1%)was significantly higher than that of control group(67.6%),with statistical sig-nificance (P<0.05). Before treatment,there was no statistical significance in ulcer area,the levels of Bcl-2 and Bax between 2 groups(P>0.05). After treatment,ulcer area decreased significantly, the level of Bcl-2 increased significantly in 2 groups,while the level of Bax decreased significantly;the improvement of observation group was more significant than that of control group,with statis-tical significance(P<0.05). There was no statistical significance in the incidence of ADR between 2 groups(P>0.05). CONCLU-SIONS:rhEGF combined with lipoic acid is effective for diabetic foot with good safety.关键词
重组人表皮生长因子/硫辛酸/糖尿病足/创面愈合/疗效Key words
Recombinant human epidermal growth factor/Lipoic acid/Diabetic foot/Wound healing/Efficacy分类
医药卫生引用本文复制引用
张祥运,丁晓斌,林秀峰,杨平,林凯..重组人表皮生长因子联合硫辛酸治疗糖尿病足的临床观察[J].中国药房,2016,27(29):4147-4149,3.
